Lab & office opened at "Nakanoshima Qross (Future Medical International Center)"
-Promoting the industrialization of regenerative medicine and creating new treatment options-
Apr 16, 2024
Rohto Pharmaceutical Co., Ltd. (Osaka City, President: Masashi Sugimoto)
has opened a research lab and office on the 16th floor of Future Medical
R&D Center in Nakanoshima Qross (Future Medical International Center),
operated by Future Medical Promotion Organization (a general incorporated
foundation, Chairman: Yoshiki Sawa), which was established by Osaka Prefecture
and 21 private companies. We have started moving in from April. Cell culture
processing facility (CPC) is scheduled to be completed in 2025. Together
with resident academia and other companies, we will promote the research
and development of new cell therapies and clinical research aimed at social
implementation, as well as the development and establishment of supply
chains in collaboration with other companies. We will contribute to people's
well-being by realizing the social implementation of regenerative medicine
as a new treatment option.
Background of participation
Our company has adopted the Rohto Group's Comprehensive Management Vision
2030, "Connect for Well-being," and while expanding into the
regenerative medicine business and food business, we contribute to people's
well-being through cutting-edge medical care, prevention, pre-disease,
and daily health. We are conducting various initiatives. In the area of
regenerative medicine, we aim to provide regenerative medicine as a new
treatment option to patients who are suffering from a lack of appropriate
treatment methods, and to establish a new model for industry-academia collaboration
in medical care, by incorporating the thought of "making regenerative
medicine more familiar and easier to use' into our business statement.
As a co-creation base for the social implementation of future medicine,
in Japan we have research bases at Advanced Medical Research Center, Fujita
Health University Tokyo and overseas at Hong Kong Science Park. By participating
in "Nakanoshima Qross (Future Medical International Center)",
we can expect further acceleration in our efforts towards social implementation
in both clinical research and industrialization, together with medical
sites, academia, and related companies.
Participation details
-
Research and development of cell therapy in collaboration with medical
sites
Based on the situation of patients and medical professionals, we will develop
cell therapy methods for seeds related to various regenerative medicines,
including mesenchymal stem cells. By conducting research and development
(reverse translational research) based on clinical information from medical
sites, it is possible to develop new cell therapy methods with high evidence.
-
Development and establishment of cell therapy supply chain through collaboration
with other tenant companies
As a cell manufacturer, we will work on developing supply chains that ensure
quality together with startup companies that have new therapeutic seeds
and related companies necessary for the industrialization of regenerative
medicine. We aim to deliver high-quality, highly therapeutically effective
cells in Japan, and to spread regenerative medicine more widely.
-
Realization of social implementation by installing Cell culture processing
facility (CPC) (scheduled for completion in 2025)
For patients needed for treatment, we will perform the contract cell processing
to medical institutions that provide treatment under free medical treatment
under the Regenerative Medicine Safety Act. By collaborating with neighboring
ophthalmology, cardiovascular, and orthopedic departments, we will contribute
to the social implementation of cell therapy with a high level of evidence.
About "Nakanoshima Qross (Future Medical International Center)"
It is an unparalleled industrialization base for future medical care, where
medical institutions, companies, startups, support organizations, etc.
are gathered under one roof. The Future Medical Promotion Organization,
a general incorporated foundation established in Osaka Prefecture in 2019
with 21 private companies, is playing a central role in building the center.
Our center is comprised of three facilities (areas): "Future Medical
MED Center'", "Future Medical R&D Center", and "Nakanoshima
International Forum'", each of which has the role of "practice",
"creation'" and "sharing'" of future medicine. By cooperating
each other among the resident companies and medical institutions and cycling
through the roles of "practice" "creation" and "sharing"
based on regenerative medicine, we aim to utilize genomic medicine, artificial
intelligence (AI), IoT, etc. and to promote the industrialization of cutting-edge
"future medicine" that responds promptly to advances in medical
technology in the future, and to drive international contributions by providing
"future medicine" to patients both domestically and internationally.